AK3280 Cream
- Generic Name
- AK3280 Cream
A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05434897
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital,Shanghal JiaoTong University School of Medicine, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
Phase 2
Not yet recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05424887
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
A Study of AK3280 in Chinese Healthy Volunteers
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04926116
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03990688
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath